X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Committing to diversity, equity and inclusion: A call to action for clinical trials

By Guest Contributor  |    November 19, 2020
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Just released: PhRMA members’ new clinical trial diversity principles

By Richard Moscicki, M.D.  |    November 18, 2020
Yesterday, PhRMA published first ever industry-wide principles on clinical trial diversity, a new chapter in the already existing “Principles on Conduct of Clinical Trials & Communication of...   Read More

How biopharmaceutical researchers are ensuring COVID-19 vaccines will be safe and effective­

By Richard Moscicki, M.D.  |    August 28, 2020
As the world continues to feel the impact of COVID-19, the biopharmaceutical industry is working around the clock to identify and develop safe and effective vaccines to prevent infection, while...   Read More

Clinical Trials Awareness Week: Recognizing unsung heroes in medical research

By Richard Moscicki, M.D.  |    May 18, 2020
This week is Clinical Trials Awareness Week — an event to recognize the importance of clinical trials, raise public awareness of clinical research and honor clinical research professionals and...   Read More

Guest Post: Preserving clinical research sites during the coronavirus pandemic

By Guest Contributor  |    April 29, 2020
Conversations and healthy debate about issues facing our industry and the healthcare system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

The biopharmaceutical industry’s unique role in responding to COVID-19

By Richard Moscicki, M.D.  |    April 2, 2020
As the outbreak of COVID-19, a disease caused by a novel strain of coronavirus, evolves in the United States and around the globe, both the private and public sectors are working around the clock...   Read More

COVID-19 Response: Supporting the frontline

By Stephen J. Ubl  |    March 30, 2020
Updated 7/13/2020 In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: to combat COVID-19, a disease caused by a novel strain of...   Read More

America’s biopharmaceutical companies are working around the clock to beat coronavirus

By Holly Campbell  |    March 20, 2020
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) underscored the industry’s commitment to finding solutions to prevent,...   Read More

ICYMI: America’s biopharmaceutical companies are taking on COVID-19

By Andrew Powaleny  |    March 16, 2020
The biopharmaceutical industry is taking on COVID-19, a disease caused by a novel strain of coronavirus, through research and development (R&D) into prevention and treatment, in-kind financial...   Read More

R&D Focus: New report shows nearly 600 medicines in development for pediatric patients

By Andrew Powaleny  |    February 13, 2020
America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates